The Epidemiology Research Core (ERC) supports population-based research by providing access to metropolitan Detroit cancer cases and the cancer registry data for research. The Core also provides epidemiology consulting and collaborates with KCI members conducfing investigations in cancer prevention, etiology, treatment and outcomes. This mission is achieved through services including rapid case ascertainment (RCA) for population-based case enrollment;collection of medical records and biospecimens for population-tjased cases;abstracting medical records for study-specific information for population-based cases;linkage of datasets to patient data for diagnostic, treatment, and outcomes data;identifying population-based control groups;oversight and support of population-based study participant recruitment and interviewing;and epidemiologic expertise and collaboration for the conduct of population-based investigations of cancer. These objectives are achievable because WSU and KCI house the Metropolitan Detroit Cancer Surveillance System (MDCSS), an NCI-funded population-based Surveillance Epidemiology and End Results (SEER) registry covering the metropolitan Detroit population of four million residents. This population represents a large number of minorities, with -25% of the 25,000 annual cancer diagnoses in the SEER catchment area being African American, making the population ideal for the study of health disparities. The ERC benefits KCI by centralizing access to SEER data and standardizing patient, physician and hospital interactions for research relying on identification of and access to study participants for populafion-based research.

Public Health Relevance

The ERC provides the necessary support to KCI members and other investigators for access to and utilization of cancer registry data and patients for entry into population-based investigations of cancer prevention, etiology, treatment and outcomes. This type of population-based cancer research is made possible by providing investigator access to the MDCSS and national SEER population data through the ERC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600860
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$154,458
Indirect Cost
$52,842
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications